

## A Prospective New Therapy Against Burkholderia Infections

Results from *in vitro* testing have shown a significant increase in the susceptibility of a variety of bacterial species and strains to antibiotics when co-administered with AlgiPharma' lead pharmaceutical product candidate, OligoG CF-5/20. In particular, tests conducted with certain strains of *Burkholderia cepacia* resulted in an up to 7-fold increase in the bacterial susceptibility to antibiotics when co-administered with OligoG CF-5/20.

Strain	OligoG CF-5/20	Ceftazidime (µg/mL)	Azithromycin (µg/mL)	Erythromycin (µg/mL)	Clarithromycin (µg/mL)
	0%	64	128	512	512
<i>Burkholderia cepacia</i> (1322, V23)	2%	32	64	256	256
	6%	8	16	128	128
	10%	<0,5	4	32	16
Fold reduction in MIC		>7	5	5	4

**Table** Minimum inhibition concentration (MIC) values for antibiotics against *Burkholderia cepacia*. Lower and declining MIC values indicate a higher effect of OligoG CF-5/20

Ongoing tests on several other *Burkholderia* strains and species show similar trends. These include: *Burkholderia multivorans*, *Burkholderia contaminans*, *Burkholderia seminalis*, *Burkholderia metallica*, and *Burkholderia cepacia*, both environmental and cystic fibrosis strains.

### About AlgiPharma

AlgiPharma is a company developing a new medicinal product for the treatment of cystic fibrosis. The product candidate, OligoG CF-5/20, represents a new treatment alternative to reduce elevated mucus viscosity and to combat pulmonary bacterial infections. In 2007, AlgiPharma was granted an Orphan Medicinal Product Designation for this product candidate from the EU commission and the EMA.

Results from preclinical safety pharmacology and toxicology studies show no abnormal clinical signs, adverse reactions or toxicological effects related to the product candidate when inhaled by rodents and dogs. In animal models, pharmacokinetic studies show a rapid excretion and elimination. In a recently concluded phase I clinical trial, the product candidate was well tolerated when administered to 28 healthy human subjects. There were no serious adverse events, discontinuations or significant changes in vital signs or laboratory values. All adverse events were mild and most probably related to the inhalation procedure and not the product candidate itself. Pharmacokinetic data from this study shows that the product candidate is not taken up systemically by the healthy human lung. A phase II clinical trial in cystic fibrosis patients is planned to commence Q4 2010. AlgiPharma would like to come into contact with interested investigators for future clinical trials.

### Contact details

#### Managing director:

Rolf Myrvold, PhD

Phone: +47 94868975

E-mail:

rolf.myrvold@algipharma.com

#### Chairman of the board:

Arne Dessen

Phone: +47 95170278

E-mail:

arne.dessen@algipharma.com